291 related articles for article (PubMed ID: 16177989)
1. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
[TBL] [Abstract][Full Text] [Related]
2. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
[TBL] [Abstract][Full Text] [Related]
3. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
Limat S; Bracco-Nolin CH; Legat-Fagnoni C; Chaigneau L; Stein U; Huchet B; Pivot X; Woronoff-Lemsi MC
Eur J Health Econ; 2006 Jun; 7(2):107-13. PubMed ID: 16474968
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
5. Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.
Miyazaki Y; Harada T; Akase T; Arakawa I; Inoue T
Clin Ther; 2009; 31 Pt 2():2433-41. PubMed ID: 20110051
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
7. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
[TBL] [Abstract][Full Text] [Related]
8. [IFL].
Yamazaki K; Yoshino T; Boku N
Gan To Kagaku Ryoho; 2006 Jul; 33(7):907-10. PubMed ID: 16835478
[TBL] [Abstract][Full Text] [Related]
9. Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.
Ashley AC; Sargent DJ; Alberts SR; Grothey A; Campbell ME; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Goldberg RM
Cancer; 2007 Aug; 110(3):670-7. PubMed ID: 17559146
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
[TBL] [Abstract][Full Text] [Related]
11. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
Lokich JJ; Moore CL; Anderson NR
Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
[TBL] [Abstract][Full Text] [Related]
12. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study.
Koperna T; Semmler D
Hepatogastroenterology; 2003; 50(54):1903-9. PubMed ID: 14696430
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).
Hebbar M; Tournigand C; Lledo G; Mabro M; André T; Louvet C; Aparicio T; Flesch M; Varette C; de Gramont A;
Cancer Invest; 2006 Mar; 24(2):154-9. PubMed ID: 16537184
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
15. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab: new drug. Metastatic colorectal cancer: good in theory, not in practice.
Prescrire Int; 2006 Jun; 15(83):94-7. PubMed ID: 16764097
[TBL] [Abstract][Full Text] [Related]
17. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
Perrocheau G; Bennouna J; Ducreux M; Hebbar M; Ychou M; Lledo G; Conroy T; Dominguez S; Faroux R; Florentin V; Douillard JY
Oncology; 2010; 79(3-4):174-80. PubMed ID: 21358204
[TBL] [Abstract][Full Text] [Related]
18. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
20. Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia.
Tran G; Hack SP; Kerr A; Stokes L; Gibbs P; Price T; Todd C
Asia Pac J Clin Oncol; 2013 Sep; 9(3):239-48. PubMed ID: 23279720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
